Harmony Gold Mining reports 61% operating profit surge but output decline and copper capex weigh on HMY stock
Can selective Bb inhibition give NovelMed Therapeutics an edge in the multibillion-dollar PNH drug market?
Read More 5 minute read Pharma Industry News Dr. Takuma Hayashi identifies LMP2 deficiency as key to uterine LMS, ushering in new era of precision cancer treatment Dr. Takuma Hayashi’s molecular discovery of LMP2 deficiency in uterine LMS marks a breakthrough in precision oncology, unlocking new diagnostic and treatment pathways. bySoujanya RaviJune 22, 2025